KRAS Mutations Make a Difference In Response to Erbitux

Update from 2008 ASCO Meeting in Chicago Three studies reported during the 2008 American Society of Clinical Oncology found that colorectal cancer patients whose tumors have mutated KRAS genes do not benefit from treatment with the EGFR-inhibitor Erbitux® (cetuximab). At the same time, patients with tumors that aren’t aren’t mutated (wild-type) have significantly better results when…  Read More

Calcium and Magnesium Infusions Reduce Neurotoxicity with Oxaliplatin

Update from 2008 ASCO Meeting in Chicago A study presented during the American Society of Clinical Oncology meeting showed that adding IV infusions of calcium and magnesium to oxaliplatin treatment reduced peripheral neuropathy. Eloxatin® (oxaliplatin) is part of the FOLFOX treatments for colorectal cancer.  As doses accumulate, patients begin to experience tingling and numbness in their…  Read More

ASCO Focuses on Personalized Medicine for Colorectal Cancer

Update from 2008 ASCO Meeting in Chicago Some thoughts from Kate Murphy. . . We’ve known for a long time that cancer isn’t one disease and that colorectal cancer isn’t one disease either.  Too often the only way to know if a treatment would work for a patient was to give it to them and wait. …  Read More

Colorectal Cancer Focus on ASCO Second Day

Update from 2008 ASCO Meeting in Chicago Some thoughts from Kate Murphy. . . A very full day at ASCO.  I began with by stopping for juice and a muffin in the Advocates’ Lounge, which is a special service provided by ASCO through their programs for people living with cancer via Cancer.Net. Advocate participation in the…  Read More

Cancer Specialists Meet at ASCO in Chicago

Update from 2008 ASCO Meeting in Chicago Some thoughts from Kate Murphy . . . I’m in Chicago for the 2008 American Society of Clinical Oncology meeting.  It’s huge!  More than 30,000 doctors and researchers from all over the world here to find out about the latest cancer research.

Some Stage II Colon and Rectal Cancers can be More Dangerous than Stage III

Advance Abstracts from ASCO 2008 How far a colon or rectal cancer penetrates through the wall of the bowel may be more important in deciding survival risks than current staging that focuses on positive lymph nodes. Five year survival statistics for a large number of rectal and cancer patients verified an earlier study that found some…  Read More